Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2026)

Aquestive Therapeutics' Change in Receivables history runs 10 years deep, the most recent figure standing at -$10.9 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 448.23% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$3.7 million (down 267.42% YoY), while the FY2025 annual figure was $10.4 million, up 1048.08% from the prior year.
• Change in Receivables was -$10.9 million for Q1 2026 at Aquestive Therapeutics, down from $6.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $7.7 million in Q1 2022 to a low of -$10.9 million in Q1 2026.
• Historically, Change in Receivables has averaged -$346882.4 across 5 years, with a median of -$104000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Change in Receivables tumbled 2132.69% in 2024, then surged 2228.57% in 2025.
• A 5-year view of Change in Receivables shows it stood at -$6.1 million in 2022, then soared by 98.29% to -$104000.0 in 2023, then sank by 2132.69% to -$2.3 million in 2024, then soared by 356.63% to $6.0 million in 2025, then tumbled by 282.85% to -$10.9 million in 2026.
• The last three Change in Receivables figures came in at -$10.9 million (Q1 2026), $6.0 million (Q4 2025), and -$63000.0 (Q3 2025), per Business Quant data.